Rosacea Treatment Using Non-thermal (cold) Atmospheric Plasma Device

The Skin Center Dermatology Group

Status: Completed

Conditions: Rosacea, Papulopustular

Treatments: Device: cold atmospheric plasma

Study type: Interventional

Funder types: Industry

Identifiers

NCT05592548

ROSACECAPRCM

Details and patient eligibility

About

10-13 patients will be enrolled to receive split face treatment: the control side will be treated with metronidazole cream, the intervention side will be treated with a cold atmospheric plasma device

Enrollment: 5 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Papulopustular rosacea of the cheeks
• Ability to complete six weeks of twice-weekly treatments

Exclusion criteria

• substantial asymmetry of disease distribution
• previous failure of topical ivermectin treatment
• presence of any other facial dermatoses
• presence of any photosensitizing disorders
• systemic tetracycline, systemic or topical ivermectin treatment within 6 weeks of start date
• current or within prior 3 months treatment with systemic immune-suppressive medication

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

Study

Experimental group

Description:

Single arm study: split face treatment

Treatment:

Device: cold atmospheric plasma